Yingyun Wang

发表

Design and molecular insights of drug-active metabolite based co-amorphous formulation: a case study of toltrazuril-ponazuril co-amorphous.

Cuiping Jiang, Binbin Li, Yingyun Wang, 2022, International journal of pharmaceutics.

Galectin-1: a link between tumor hypoxia and tumor immune privilege.

Shuchun Zhao, A. Koong, K. O'Byrne, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Special architecture and anti-wear strategies for giant panda tooth enamel: Based on wear simulation findings

Gang Liu, Zichen Liu, Yuanheng Wu, 2022, Frontiers in Veterinary Science.

Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.

Yu Ding, Michelle Mathur, Jiong Lan, 2013, ACS medicinal chemistry letters.

Effect of GS-441524 in combination with the 3C-like protease inhibitor GC376 on the treatment of naturally transmitted feline infectious peritonitis

Liu Yang, Yang Bai, Yipeng Jin, 2022, Frontiers in Veterinary Science.

Cryotherapy mediates histopathological and microstructural changes during the treatment of skin and subcutaneous tumors in dogs.

D. Lin, Yang Bai, Xuezhi Yu, 2020, Cryobiology.

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Audrey Kauffmann, Jianjun Yu, Yumin Dai, 2014, Clinical Cancer Research.

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.

Jianjun Yu, Yumin Dai, Janet Sim, 2013, Blood.

Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity

S. Rutz, Z. Modrušan, James Ziai, 2022, Nature Immunology.

Sishen Wan Treats Ulcerative Colitis in Rats by Regulating Gut Microbiota and Restoring the Treg/Th17 Balance

Jie Li, Yan Wang, Yingyun Wang, 2022, Evidence-based complementary and alternative medicine : eCAM.

Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor

Mallika Singh, A. Gill, W. C. Gustafson, 2022, Cancer Research.

Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.

Yumin Dai, Yanchen Zhang, Mika K Lindvall, 2015, Journal of medicinal chemistry.

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.

W. Sellers, M. P. Dillon, Y. Mishina, 2020, Journal of medicinal chemistry.

Complexation of Apigenin and Oxymatrine Leading to Enhanced Anti-inflammatory Activity.

Hongzhi Du, Yingyun Wang, Daniel T. N. Yuan, 2023, Journal of natural products.

A comparative study of skin transcriptomes and histological observations for black and white hair colors of giant panda

Gang Liu, Yipeng Jin, Yingyun Wang, 2022, Frontiers in Medicine.

Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

M. P. Dillon, Mallika Singh, E. Lees, 2017, Journal of medicinal chemistry.

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.

Joshua M. Korn, W. Sellers, F. Shen, 2018, Cancer research.

Characterization of macular thickness changes in Leber’s hereditary optic neuropathy by optical coherence tomography

Houbin Huang, Hong-yang Li, Shuo Zhao, 2014, BMC Ophthalmology.

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

M. Lindvall, A. Kauffmann, C. Fanton, 2014, Clinical Cancer Research.